Issue link: http://osercommunicationsgroup.uberflip.com/i/562622
C h a i n D r u g s t o r e D a i l y S u n d a y, A u g u s t 2 3 , 2 0 1 5 3 4 BRIDGING GAPS BETWEEN YOUR PRODUCT AND RETAIL By Greg Tucker, Chief Executive Officer, Bay Cities Did you know that 36 percent of people have changed brands from a previously purchased product just because of the packaging? And that more than one in six purchases are sold because of a display placement? With only three seconds to grab the attention of your audience before they lose interest, displays continue to prove their worth time and time again. This is where Bay Cities comes in. With nearly 60 years of experience in the packaging and display industry, Bay Cities has the expertise and know-how to pro- mote your brand and bridge the gap between your product and retail. We have incredibly close relationships with major retailers across the country, allowing for intimate knowledge of each store's specifi- cations for displays and packaging, includ- ing mass retailers, specialty, drug, chain and club stores. Our team obtains the knowledge when it comes to understand- ing the combination of structure, materials, size and handling that is required to meet a specific retailer's guidelines. Our Bentonville Division was opened specifically because of our inti- mate relationship with Walmart, one of the world's biggest retailers. We often meet with Walmart influencers months in advance to plan nationwide programs, create department approved style guides and manage pro- motional time lines. We are a trusted packaging supplier for them and truly understand how to navigate within their ecosystem. Recently, Walmart came to us with a Spring Valley Vitamin program that focused on showcas- ing a variety of supplements from multiple suppliers. They knew they could count on us to build a display that would exceed their expectations, while simultaneously working to ensure precise product place- ment. After consulting with Spring Valley, our in-house structural and graphic design team developed a shallow dump bin that was only four inches deep in order to be easily accessible to customers, but also appearing to be full. This was a critical component for their program because we were placing multiple suppliers into a single pre-pack display. After final testing, manufactur- ing, and packout and fulfill- ment, we distributed the dump bins to over 5,200 Walmarts over a three month period. Our close relationship and expertise with Walmart allowed us to handle all logistics within the program on behalf of the client. With promotions constantly chang- ing, it's important to ensure your brand stands out. Here at Bay Cities, we know how to do just that, and do it well. Let us create a packaging or point-of-purchase display program for you that sets you apart at retail. Visit Bay Cities at booth #2449. For more information, call 562.948.3751 or email info@bay-cities.com. ASCEND LABS CONTINUES GROWTH, LOOKS TO FUTURE Ascend Labs is continuing its steady growth that has led it to be named as one of the industry's fastest growing young companies. Using a strategy that com- bines service, pricing, quality product and availability, the company has suc- cessfully launched three new products so far this year, including exclusives on Mycophenolate Suspension and Benzonatate 150mg. Commenting on the new items, John Dillaway Ascend's Executive Vice President of Sales and Marketing, says the items are in keeping with Ascend's desire to identify product needs and bring these to market in a way that benefits both its customers and patients. Ascend, the U.S. arm of Alkem Laboratories, one of the leading pharma- ceutical companies in India, is building a strong infrastructure which will allow it to have a significant presence going for- ward. An acquisition of Norac, a DEA API company in California, was the first step. More recently, the company has completed an acquisition of Long Pharma, a formulation developer and manufacturer in St. Louis. The company continues to look for additional acquisi- tion opportunities that will allow it to capitalize on its strengths. The company's R&D is centered in India, and has completed the develop- ment and submission of more than 50 molecules to the FDA. With a focus on harder to manufacture drugs and more complex science, Ascend expects to distinguish itself from others as these products receive approval from the FDA. The India and international based teams are headed by Amit Ghare, who has extensive knowledge of both the U.S. market and the reg- ulatory environment. Also, S. Venkatesh has relocated with his family from Mumbai this past January to lead the U.S. division. He has extensive experience both in branded and generic markets, spending time with both DRL and Pfizer while in India. Ascend is preparing for its growth by further developing its U.S. sales team. Dillaway states the company has recently welcomed Jenny Fox and Kylan Ward. Jenny comes with many years of experi- ence at Ranbaxy, and Kylan moves to the prescription side of the business after spending time on the nutraceutical side. They will complement Schuyler VanWinkle, Greg Watkins and Lynette Piers in dealing with Ascend's national accounts and continuing the Ascend tradition of providing superior service. With a strong team in place and a robust pipeline, customers can expect to be hearing quite a bit from Ascend. Newly approved Mycophenolate Suspension joins prior approvals on Mycophenolate, including the 250mg caps and 500mg tabs, making Ascend the only generic company marketing the whole Mycophenolate family. These new approvals, coupled with its existing product offers and robust pipeline, will position Ascend to continue the fast growth it has experienced. Visit Ascend at booth #2206. SPECIALTY GENERICS FROM MALLINCKRODT For nearly 150 years, the Mallinckrodt name has represented quality products, business integrity and service to patients, customers and communities. Its future- focused vision and dedication to improv- ing lives is matched only by its distinct approach to managing complexity. As an independent global specialty biopharmaceutical company focused on controlled substances and adjacent areas, as well as therapeutic drugs for autoim- mune and rare disease specialty areas, neonatal critical care respiratory thera- pies, analgesics and central nervous sys- tem drugs and diagnostic medical imag- ing agents, Mallinckrodt Pharmaceuticals continues to apply its unique strengths, experience and expertise to bring prod- ucts to the market that provide unmet value for physicians and patients it joint- ly serves. At Mallinckrodt, the common thread critical to its past and future success is the strong ability to master and manage complexity. Simply put, Mallinckrodt strives to make the complex simple. It is driven by an intense energy, and led by engaged and high-performing people. This forward momentum promises to expand the company's horizons even fur- ther toward its continued goal to be a top- performing specialty biopharmaceutical company. Specialty Generics Leader Mallinckrodt's Specialty Generics busi- ness developed as a natural extension of the company's Active Pharmaceuticals Ingredients (API) business in the mid- 1990s. Many of the company's generic products use the API produced by Mallinckrodt, which allows it to ensure reliable and high-quality supply. Today, its Specialty Generics busi- ness offers a comprehensive product portfolio with industry-leading expertise across pain management, attention- deficit hyperactivity disorder and addic- tion treatment. More than 60 million pre- scriptions are filled annually with Mallinckrodt's generic products. Mallinckrodt is also one of the world's leading producers of bulk acetamino- phen. Its top eight generic products are each within the top three in market share for their respective categories. Mallinckrodt is vertically integrated to ensure quality control during every step of a product's devel- opment – from active ingredient processing through formulation, man- ufacturing and distribution. Through its global operations platform, its ability to manufacture complex products and deliver them efficiently to customers reflects Mallinckrodt's core values that it has held true to since 1867 – quality, integrity and service. Investing in the Future The same goal of providing high-quality, innovative products that began almost a century and a half ago with the Mallinckrodt brothers still exists today. It has benefited from a productive Research and Development (R&D) team, with U.S. Food and Drug Administration (FDA) approval of 12 new products company- wide since 2010. The company's devel- opment pipeline remains focused in areas where it thinks it can bring differentiated value to the marketplace, and the Specialty Generics portfolio is a high pri- ority for R&D. The company has also invested mil- lions of dollars in research efforts focus- ing on exploring the abuse-deterrent potential of its proprietary formulation technologies. Mallinckrodt understands the importance of developing abuse- deterrent technologies that can be used in both branded and generic medi- cines that will effectively make products less attractive to potential abusers, while at the same time providing patients, who depend on its medicines for relief of diagnosed pain, with a wide range of safe, affordable options. Specifically, Mallinckrodt's Specialty Generics supply chain con- tinues to invest in several infrastruc- ture and capacity improvements to consistently deliver the high-quality products customers need. Recent expansion of the high-volume manu- facturing facility in Hobart, New York, will increase production of its generic pharmaceuticals, and new packaging lines will improve product output. It has also invested in Mallinckrodt's API business to increase capacity and reliability of raw materials for generic pharmaceuticals. In closing, Mallinckrodt's specialty generic drug products allow for patient accessibility to broader healthcare options, and continue to be a key area of focus for the company. Visit Mallinckrodt at booth #115. For more information, call 800.325.8888 or go to www.mallinckrodt.com.